Biocon says it is moving from an expansion phase to a focus on capacity utilization, margin expansion, and stronger returns. After major investments to build global capabilities, the company reported 13% revenue growth for FY26, but net profit fell significantly. Biocon is also aiming for sustainable profitable growth while exploring in-licensing for its biosimilars portfolio.
Adani Cement is choosing a more cautious growth path by pushing higher utilization of its current facilities rather than racing toward ambitious FY28 targets. Management said it may recalibrate capital expenditure plans as it optimizes existing capacities, aiming to better leverage its 109 million tonnes production base. The CEO also hinted that target timelines could shift to FY30.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
